Rohto Pharmaceutical Co.,Ltd. (FRA:UC1)
Germany · Delayed Price · Currency is EUR 12.80
-0.20 (-1.54%)
At close: Feb 20, 2026
Rohto Pharmaceutical Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Net Income | 42,331 | 41,518 | 34,290 | 27,953 | 23,006 |
Depreciation & Amortization | 13,143 | 8,687 | 7,801 | 7,673 | 6,748 |
Loss (Gain) From Sale of Assets | 175 | 348 | 1,338 | 892 | 1,691 |
Loss (Gain) From Sale of Investments | -1,896 | 798 | 285 | 798 | -750 |
Loss (Gain) on Equity Investments | -166 | 289 | -56 | -143 | -396 |
Other Operating Activities | -10,932 | -10,218 | -6,995 | -10,347 | -9,508 |
Change in Accounts Receivable | 1,950 | -6,787 | -7,560 | -30 | 2,464 |
Change in Inventory | -4,597 | -4,029 | -6,105 | -3,061 | 3,188 |
Change in Accounts Payable | -1,288 | 1,679 | 1,716 | 3,323 | -2,811 |
Change in Other Net Operating Assets | -1,803 | 1,960 | 6,210 | 192 | -3,624 |
Operating Cash Flow | 36,917 | 34,245 | 30,924 | 27,250 | 20,008 |
Operating Cash Flow Growth | 7.80% | 10.74% | 13.48% | 36.20% | 5.08% |
Capital Expenditures | -9,080 | -7,979 | -8,473 | -10,267 | -8,721 |
Sale of Property, Plant & Equipment | 26 | 272 | 109 | 12 | 597 |
Cash Acquisitions | -74,479 | - | - | -1,203 | -1,516 |
Sale (Purchase) of Intangibles | -1,481 | -933 | -1,435 | -1,061 | -1,583 |
Investment in Securities | -3,563 | -7,376 | -3,299 | -3,652 | 1,844 |
Other Investing Activities | 163 | 230 | 178 | 128 | - |
Investing Cash Flow | -89,170 | -16,317 | -13,176 | -16,406 | -10,237 |
Short-Term Debt Issued | - | 656 | - | 1,273 | - |
Long-Term Debt Issued | 40,178 | 1,605 | 220 | 9,450 | 2,883 |
Total Debt Issued | 40,178 | 2,261 | 220 | 10,723 | 2,883 |
Short-Term Debt Repaid | -2,310 | - | -1,341 | - | -169 |
Long-Term Debt Repaid | -5,961 | -3,484 | -8,761 | -3,133 | -1,880 |
Total Debt Repaid | -8,271 | -3,484 | -10,102 | -3,133 | -2,049 |
Net Debt Issued (Repaid) | 31,907 | -1,223 | -9,882 | 7,590 | 834 |
Repurchase of Common Stock | -5,000 | - | - | - | - |
Common Dividends Paid | -7,072 | -5,475 | -4,676 | -3,422 | -2,965 |
Other Financing Activities | 15,484 | -7,086 | -1,641 | -698 | -216 |
Financing Cash Flow | 35,319 | -13,784 | -16,199 | 3,470 | -2,347 |
Foreign Exchange Rate Adjustments | 3,374 | 4,703 | 5,236 | 4,335 | 96 |
Miscellaneous Cash Flow Adjustments | 219 | 23 | 1 | 1 | 68 |
Net Cash Flow | -13,341 | 8,870 | 6,786 | 18,650 | 7,588 |
Free Cash Flow | 27,837 | 26,266 | 22,451 | 16,983 | 11,287 |
Free Cash Flow Growth | 5.98% | 16.99% | 32.20% | 50.47% | -16.11% |
Free Cash Flow Margin | 9.02% | 9.70% | 9.41% | 8.51% | 6.23% |
Free Cash Flow Per Share | 121.61 | 114.80 | 98.13 | 74.23 | 49.33 |
Cash Interest Paid | 888 | 200 | 247 | 228 | 143 |
Cash Income Tax Paid | 11,219 | 9,970 | 6,937 | 8,731 | 7,771 |
Levered Free Cash Flow | 16,651 | 15,301 | 12,450 | 11,698 | 8,861 |
Unlevered Free Cash Flow | 17,244 | 15,423 | 12,604 | 11,853 | 8,952 |
Change in Working Capital | -5,738 | -7,177 | -5,739 | 424 | -783 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.